The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone

BACKGROUND: The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months. Survival beyond 3 years is rare. For selected groups of patients with limited MGC, retrospective studies have shown improved overall survival following gastr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerkar, Sid P, Kemp, Clinton D, Duffy, Austin, Kammula, Udai S, Schrump, David S, Kwong, King F, Quezado, Martha, Goldspiel, Barry R, Venkatesan, Aradhana, Berger, Ann, Walker, Melissa, Toomey, Mary Ann, Steinberg, Seth M, Giaccone, Guiseppe, Rosenberg, Steven A, Avital, Itzhak
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Study protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803175/
https://www.ncbi.nlm.nih.gov/pubmed/20030854
http://dx.doi.org/10.1186/1745-6215-10-121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803175/
https://www.ncbi.nlm.nih.gov/pubmed/20030854
http://dx.doi.org/10.1186/1745-6215-10-121

Ejemplares similares